Story perspectives

Immunovant shares surge 35% after robust RA results

5/21/2026

Summary

Immunovant Shares Surge

Immunovant's shares jumped 35.3% to $35.56 after the company released 16-week results for its rheumatoid arthritis drug IMVT-1402.
The 16-week study reported overall ACR20/50/70 rates of 72.7%/54.5%/35.8% and, in patients who had failed JAK inhibitor and anti-TNF therapy, rates of 72.0%/53.3%/37.4%.
Immunovant posted a Q4 net loss of $147.9 million ($0.73 per share) and retained roughly $902.1 million in cash.

Summary

Immunovant Ramps R&D

R&D spending rose to $142.3 million in Q4, up from $93.7 million a year earlier.
$39 million of the increase covered contractual costs from ending batoclimab after two Phase 3 failures.
The cutaneous lupus erythematosus proof-of-concept trial completed enrollment, with results expected in the second half of 2026.
Immunovant will allocate $1 million in cash to fund a Graves’ disease launch of IMVT-1402 while targeting registrational trials in Graves’ disease and myasthenia gravis in 2027.

1 of 2

Immunovant Shares Surge

Immunovant's shares jumped 35.3% to $35.56 after the company released 16-week results for its rheumatoid arthritis drug IMVT-1402.
The 16-week study reported overall ACR20/50/70 rates of 72.7%/54.5%/35.8% and, in patients who had failed JAK inhibitor and anti-TNF therapy, rates of 72.0%/53.3%/37.4%.
Immunovant posted a Q4 net loss of $147.9 million ($0.73 per share) and retained roughly $902.1 million in cash.

1 / 2